Predictive and prognostic molecular markers for cancer medicine

Therapeutic Advances in Medical Oncology

Volumn 2, Issue 2, 2010, Pages 125-148

  Mehta, Sunali ^a   Lasham, Annette ^a   Blenkiron, Cherie ^a   Shelling, Andrew ^b   Muthukaruppan, Anita ^b   Laking, George ^a   Print, Cristin ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

biomarker; cancer; microarray; pathology; prognosis; treatment response

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CYCLIN D1; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GELATINASE A; GLUCURONOSYLTRANSFERASE 1A1; HERMES ANTIGEN; IRINOTECAN; K RAS PROTEIN; KI 67 ANTIGEN; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; TAMOXIFEN; THYMIDINE PHOSPHORYLASE; TRASTUZUMAB; TUMOR MARKER; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN;

ADVANCED CANCER; BLADDER CANCER; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CLINICAL TRIAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DNA SEQUENCE; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL STROMAL TUMOR; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MELANOMA; METABOLOMICS; MICROARRAY ANALYSIS; ONCOGENE C KIT; ONCOLOGY; PANCREAS CANCER; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RECTUM CANCER; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TREATMENT RESPONSE;

EID: 77955590529     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834009360519     Document Type: Review

References (248)

1. Abbod, M.F., Catto, J.W., Linkens, D.A. and Hamdy, F.C. ( 2007) Application of artificial intelligence to the management of urological cancer. J Urol 178: 1150-1156.
2. Abbott, L.H. and Michor, F. ( 2006) Mathematical Models of Targeted Cancer Therapy. Br J Cancer 95: 1136-1141.
3. Abdueva, D., Wing, M.R., Schaub, B. and Triche, T.J. ( 2007) Experimental comparison and evaluation of the affymetrix exon and U133plus2 genechip arrays. PloS ONE 2: e913.
4. Acharya, C.R., Hsu, D.S., Anders, C.K., Anguiano, A., Salter, K.H., Walters, K.S. et al. (2008) Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA 299: 1574-1587.
5. Adjei, A.A., Christian, M. and Ivy, P. (2009) Novel designs and end points for phase II clinical trials. Clin Cancer Res 15: 1866-1872.
6. Ahmed, F.E. ( 2005) Molecular markers that predict response to colon cancer therapy. Expert Rev Mol Diagn 5: 353-375.
7. Alvarado, M.D., Jensen, E.H. and Yeatman, T.J. ( 2006) The potential role of gene expression in the management of primary and metastatic colorectal cancer. Cancer Control 13: 27-31.
8. Amado, R.G., Wolf, M., Peeters, M., van Cutsem, E., Siena, S., Freeman, D.J. et al. (2008) Wild-type Kras is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
9. Anders, C.K., Acharya, C.R., Hsu, D.S., Broadwater, G., Garman, K., Foekens, J.A. et al. (2008) Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PloS ONE 3: e1373.
10. Andre, F. and Pusztai, L. ( 2006) Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol 3: 621-632.
11. Andre, F., Michiels, S., Dessen, P., Scott, V., Suciu, V., Uzan, C. et al. (2009) Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol 10: 381-390.
12. Anjomshoaa, A., Lin, Y.H., Black, M.A., McCall, J.L., Humar, B., Song, S. et al. (2008) Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer. Br J Cancer 99: 966-973.
13. Arango, D., Wilson, A.J., Shi, Q., Corner, G.A., Aranes, M.J., Nicholas, C. et al. (2004) Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91: 1931-1946.
14. Arriagada, R., Bergman, B., Dunant, A., Le Chervalier, T., Pignon, J.P. and Vansteenkiste, J. ( 2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350: 351-360.
15. Avard, D. and Knopper, B.M. (2009) Genomic medicine: considerations for health professionals and the public. Genome Med 1: 25-26.
16. Ayers, M., Symmans, W.F., Stec, J., Damokosh, A.I., Clark, E., Hess, K. et al. (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22: 2284-2293.
17. Barnett, G.C., West, C.M., Dunning, A.M., Elliott, R.M., Coles, C.E., Pharoah, P.D. et al. (2009) Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 9: 134-142.
18. Barry, M.J. ( 2009) Screening for prostate cancer-the controversy that refuses to die. N Engl J Med 360: 1351-1354.
19. Bartels, C.L. and Tsongalis, G.J. (2009) MicroRNAs: novel biomarkers for human cancer. Clin Chem 55: 623-631.
20. Basil, C.F., Zhao, Y., Zavaglia, K., Jin, P., Panelli, M.C., Voiculescu, S. et al. (2006) Common cancer biomarkers. Cancer Res 66: 2953-2961.
21. Bastian, P.J., Yegnasubramanian, S., Palapattu, G.S., Rogers, C.G., Lin, X., de Marzo, A.M. et al. (2004) Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol 46: 698-708.
22. Belinsky, S.A. ( 2004) Gene promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4: 1-11.
23. Bild, A.H., Potti, A. and Nevins, J.R. ( 2006a) Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 6: 735-741.
24. Bild, A.H., Yao, G., Chang, J.T., Wang, Q., Potti, A., Chasse, D. et al. (2006 b) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
25. Blenkiron, C. and Miska, E.A. ( 2007) miRNAs in cancer: approaches, aetiology, diagnostics and therapy. Hum Mol Genet 16(Spec No 1): R106-R113
26. Blenkiron, C., Goldstein, L.D., Thorne, N.P., Spiteri, I., Chin, S.F., Dunning, M.J. et al. (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8: R214.
27. Bloomston, M., Frankel, W.L., Petrocca, F., Volinia, S., Alder, H., Hagan, J.P. et al. (2007) MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297: 1901-1908.
28. Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J.T., Aparicio, J., de Braud, F. et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671.
29. Bowers, J., Mitchell, J., Beer, E., Buzby, P.R., Causey, M., Efcavitch, J.W. et al. (2009) Virtual terminator nucleotides for next-generation dna sequencing. Nat Methods 6: 593-595.
30. Brindle, K. ( 2008) New approaches for imaging tumour responses to treatment. Nat Rev Cancer 8: 94-107.
31. Bringuier, P.P., Umbas, R., Schaafsma, H.E., Karthaus, H.F., Debruyne, F.M. and Schalken, J.A. ( 1993) Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 53: 3241-3245.
32. Bui, M.H., Seligson, D., Han, K.R., Pantuck, A.J., Dorey, F.J., Huang, Y. et al. (2003) Carbonic anhydrase Ix is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9: 802-811.
33. Bukhari, M.H. and Akhtar, Z.M. (2009) Comparison of accuracy of diagnostic modalities for evaluation of breast cancer with review of literature. Diagn Cytopathol 37: 416-424.
34. Bustin, S.A. and Nolan, T. ( 2004) Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J Biomol Tech 15: 155-166.
35. Calin, G.A., Dumitru, C.D., Shimizu, M., Bichi, R., Zupo, S., Noch, E. et al. (2002) Frequent deletions and down-regulation of micro-RNA genes Mir 15 and Mir 16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99: 15524-15529.
36. Cardoso, F., van ‘t Veer, L., Rutgers, E., Loi, S., Mook, S. and Piccart-Gebhart, M.J. ( 2008) Clinical application of the 70-gene profile: the Mindact trial. J Clin Oncol 26: 729-735.
37. Carey, F.A., Lamb, D. and Bird, C.C. ( 1990) Importance of sampling method in DNA analysis of lung cancer. J Clin Pathol 43: 820-823.
38. Chang, H.Y., Nuyten, D.S., Sneddon, J.B., Hastie, T., Tibshirani, R., Sorlie, T. et al. (2005) Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 102: 3738-3743.
39. Chang, J.T., Carvalho, C., Mori, S., Bild, A.H., Gatza, M.L., Wang, Q. et al. (2009) A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell 34: 104-114.
40. Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K. et al. (2008) Characterization of micrornas in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006.
41. Chin, L. and Gray, J.W. ( 2008) Translating insights from the cancer genome into clinical practice. Nature 452: 553-563.
42. Clark, T.A., Schweitzer, A.C., Chen, T.X., Staples, M.K., Lu, G., Wang, H. et al. (2007) Discovery of tissue-specific exons using comprehensive human exon microarrays. Genome Biol 8: R64.
43. Cloughesy, T.F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S. et al. (2008) Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5: e8.
44. Coate, L.E., John, T., Tsao, M. and Shepherd, F.A. (2009) Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet 10: 1001-1010.
45. Cobo, M.S., Massuti, B., Moran, T., Chaib, L., Pérez-Roca, U., Jiménez, D. et al. (2008) Spanish Customized Adjuvant Trial (SCAT) based on BRCA 1 mRNA levels. Proc Am Soc Clin Oncol 26: abstr 7533.
46. Cohen, S.J., Punt, C.J., Iannotti, N., Saidman, B.H., Sabbath, K.D., Gabrail, N.Y. et al. (2009) Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20: 1223-1229.
47. Contractor, K.B. and Aboagye, E.O. ( 2009) Monitoring predominantly cytostatic treatment response with 18f-FDG PET. J Nucl Med 50(Suppl 1): 97S-105S.
48. Cordon-Cardo, C., Kotsianti, A., Verbel, D.A., Teverovskiy, M., Capodieci, P., Hamann, S. et al. (2007) Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest 117: 1876-1883.
49. Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Matera, J., Miller, M.C. et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791.
50. Davis, L.M., Harris, C., Tang, L., Doherty, P., Hraber, P., Sakai, Y. et al. (2007) Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma. J Mol Diagn 9: 327-336.
51. Dematteo, R.P., Ballman, K.V., Antonescu, C.R., Maki, R.G., Pisters, P.W., Demetri, G.D. et al. (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373: 1097-1104.
52. Donovan, M.J., Khan, F.M., Fernandez, G., Mesa-Tejada, R., Sapir, M., Zubek, V.B. et al. (2009) Personalized prediction of tumor response and cancer progression on prostate needle biopsy. J Urol 182: 125-132.
53. Dowsett, M., Houghton, J., Iden, C., Salter, J., Farndon, J., A'hern, R. et al. (2006) Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, Egf receptor and Her 2 status. Ann Oncol 17: 818-826.
54. Dowsett, M., Smith, I.E., Ebbs, S.R., Dixon, J.M., Skene, A., A'Hern, R. et al. (2007) Prognostic value of Ki 67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99: 167-170.
55. Dunn, J., Baborie, A., Alam, F., Joyce, K., Moxham, M., Sibson, R. et al. (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101: 124-131.
56. Dworkin, A.M., Huang, T.H. and Toland, A.E. (2009) Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol 19: 165-171.
57. Early Breast Cancer Trialists’ Collaborative Group. ( 1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467.
58. Easton, D.F., Pooley, K.A., Dunning, A.M., Pharoah, P.D., Thompson, D., Ballinger, D.G. et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087-1093.
59. Edgar, R., Domrachev, M. and Lash, A.E. ( 2002) Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
60. Elledge, R.M., Green, S., Pugh, R., Allred, D.C., Clark, G.M., Hill, J. et al. (2000) Estrogen receptor (Er) and progesterone receptor (Pgr), by ligand-binding assay compared with Er, Pgr and Ps2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a southwest oncology group study. Int J Cancer 89: 111-117.
61. Esteller, M. ( 2008) Epigenetics in cancer. N Engl J Med 358: 1148-1159.
62. Fan, C., Oh, D.S., Wessels, L., Weigelt, B., Nuyten, D.S., Nobel, A.B. et al. (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355: 560-569.
63. Fang, Z., Soleymani, L., Pampalakis, G., Yoshimoto, M., Squire, J.A., Sargent, E.H. et al. (2009) Direct profiling of cancer biomarkers in tumor tissue using a multiplexed nanostructured microelectrode integrated circuit. ACS Nano 3: 3207-3213.
64. Faratian, D. and Bartlett, J. ( 2008) Predictive markers in breast cancer-the future. Histopathology 52: 91-98.
65. Faustino, N.A. and Cooper, T.A. ( 2003) Pre-mRNA splicing and human disease. Genes Dev 17: 419-437.
66. Ferrone, C.R., Finkelstein, D.M., Thayer, S.P., Muzikansky, A., Fernandez-Delcastillo, C. and Warshaw, A.L. ( 2006) Perioperative Ca19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 24: 2897-2902.
67. Fey, M.F. and Tobler, A. ( 1996) Tumour heterogeneity and clonality-an old theme revisited. Ann Oncol 7: 121-128.
68. Furusato, B., Shaheduzzaman, S., Petrovics, G., Dobi, A., Seifert, M., Ravindranath, L. et al. (2007) Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens. Prostate Cancer Prostatic Dis 11: 194-197.
69. Galon, J., Franchimont, D., Hiroi, N., Frey, G., Boettner, A., Ehrhart-Bornstein, M. et al. (2002) Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 16: 61-71.
70. Gardina, P.J., Clark, T.A., Shimada, B., Staples, M.K., Yang, Q., Veitch, J. et al. (2006) Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 7: 325.
71. Garman, K.S., Acharya, C.R., Edelman, E., Grade, M., Gaedcke, J., Sud, S. et al. (2008) A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A 105: 19432-19437.
72. Ge, H., Walhout, A.J. and Vidal, M. ( 2003) Integrating ‘omic’ information: a bridge between genomics and systems biology. Trends Genet 19: 551-560.
73. GenomeWeb (2009) Pharmacogenetic-based prescribing slow to take hold. GenomeWeb Daily News; 16 February 2009.
74. Gerdes, J., Lemke, H., Baisch, H., Wacker, H.H., Schwab, U. and Stein, H. ( 1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715.
75. Gevaert, O., de Smet, F., Timmerman, D., Moreau, Y. and de Moor, B. ( 2006) Predicting the prognosis of breast cancer by integrating clinical and microarray data with bayesian networks. Bioinformatics 22: e184-e190
76. Geyer, F.C. and Reis-Filho, J.S. (2009) Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? Int J Surg Path 17: 285-302.
77. Glas, A., Roepman, P., Salazar, R., Capella, G., Moreno, V., Westerga, J. et al. (2009) Development and validation of a robust prognostic and predictive signature for colorectal cancer (CRC) patients. J Clin Oncol 27: (supplement abstract 4036).
78. Goldstein, L.J., Gray, R., Badve, S., Childs, B.H., Yoshizawa, C., Rowley, S. et al. (2008) Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26: 4063-4071.
79. Gordon, M.A., Gil, J., Lu, B., Zhang, W., Yang, D., Yun, J. et al. (2006) Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics 7: 67-88.
80. Guffanti, A., Iacono, M., Pelucchi, P., Kim, N., Solda, G., Croft, L.J. et al. (2009) A transcriptional sketch of a primary human breast cancer by 454 deep sequencing. BMC Genomics 10: 163.
81. Gutierrez, M.E., Kummar, S. and Giaccone, G. (2009) Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 6: 259-265.
82. Gutman, S. and Kessler, L.G. ( 2006) The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer 6: 565-571.
83. Hallstrom, T.C., Mori, S. and Nevins, J.R. ( 2008) An E2f1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 13: 11-22.
84. Hanauer, D.A., Rhodes, D.R., Sinha-Kumar, C. and Chinnaiyan, A.M. ( 2007) Bioinformatics approaches in the study of cancer. Curr Mol Med 7: 133-141.
85. Hargreaves, R.J. ( 2008) The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther 83: 349-353.
86. Hayden, E.C. ( 2009a) Genomics shifts focus to rare diseases. Nature 461: 24.
87. Hayden, E.C. (2009 b) Personalized cancer therapy gets closer. Nature 458: 131-132.
88. Hegde, P., Qi, R., Gaspard, R., Abernathy, K., Dharap, S., Earle-Hughes, J. et al. (2001) Identification of tumor markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray. Cancer Res 61: 7792-7797.
89. Hoskins, J.M., Carey, L.A. and McLeod, H.L. (2009) CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 9: 576-586.
90. Huang, E., West, M. and Nevins, J.R. ( 2003) Gene expression profiling for prediction of clinical characteristics of breast cancer. Recent Prog Horm Res 58: 55-73.
91. Huang, Y.W., Jansen, R.A., Fabbri, E., Potter, D., Liyanarachchi, S., Chan, M.W. et al. (2009) Identification of candidate epigenetic biomarkers for ovarian cancer detection. Oncol Rep 22: 853-861.
92. Huerta, S., Harris, D.M., Jazirehi, A., Bonavida, B., Elashoff, D., Livingston, E.H. et al. (2003) Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol 22: 663-670.
93. Ioannidis, J.P. ( 2009) Personalized genetic prediction: too limited, too expensive, or too soon? Ann Int Med 150: 139-141.
94. Jaeger, J., Koczan, D., Thiesen, H.J., Ibrahim, S.M., Gross, G., Spang, R. et al. (2007) Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 13: 806-815.
95. James, C.R., Quinn, J.E., Mullan, P.B., Johnston, P.G. and Harkin, D.P. ( 2007) BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 12: 142-150.
96. Josephs, D., Spicer, J. and O'Doherty, M. ( 2009) Molecular imaging in clinical trials. Target Oncol. Epub 21September 2009.
97. Kalscheuer, S., Zhang, X., Zeng, Y. and Upadhyaya, P. ( 2008) Differential expression of microRNAs in early-stage neoplastic transformation in the lungs of F 344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 29: 2394-2399.
98. Kanai, Y. ( 2007) Alteration of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcinogenesis 28: 2434 - 2442.
99. Kanehisa, M., Goto, S., Hattori, M., Aoki-Kinoshita, K.F., Itoh, M., Kawashima, S. et al. (2006) From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34: D354-D357
100. Kapp, A.V., Jeffrey, S.S., Langerod, A., Borresen-Dale, A.L., Han, W., Noh, D.Y. et al. (2006) Discovery and validation of breast cancer subtypes. BMC Genomics 7: 231.
101. Karsdal, M.A., Henriksen, K., Leeming, D.J., Mitchell, P., Duffin, K., Barascuk, N. et al. (2009) Biochemical markers and the FDA critical path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 14: 181-202.
102. Katsanis, S.H., Javitt, G. and Hudson, K. ( 2008) Public health. A case study of personalized medicine. Science 320: 53-54.
103. Khoury, M.J., Gwinn, M., Yoon, P.W., Dowling, N., Moore, C.A. and Bradley, L. ( 2007) The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 9: 665-674.
104. Kim, G.P., Colangelo, L.H., Wieand, H.S., Paik, S., Kirsch, I.R., Wolmark, N. et al. (2007) Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 25: 767-772.
105. Kim, C., Taniyama, Y. and Paik, S. (2009) Gene expression-based prognostic and predictive markers for breast cancer: a primer for practicing pathologists. Arch Pathol Lab Med 133: 855-859.
106. Koscielny, S. ( 2008) Critical review of microarray-based prognostic tests and trials in breast cancer. Curr Opin Obstet Gynecol 20: 47-50.
107. Kuremsky, J.G., Tepper, J.E. and McLeod, H.L. (2009) Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 74: 673-688.
108. Laking, G., Lord, J. and Fischer, A. ( 2006) The economics of diagnosis. Health Econ 15: 1109-1120.
109. Lazebnik, Y. ( 2002) Can a biologist fix a radio? Or, what I learned while studying apoptosis. Cancer Cell 2: 179-182.
110. Lebeau, A., Deimling, D., Kaltz, C., Sendelhofert, A., Iff, A., Luthardt, B. et al. (2001) Her-2/Neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19: 354-363.
111. Lee, R.C., Feinbaum, R.L. and Ambros, V. ( 1993) The C. elegans heterochronic gene Lin-4 encodes small RNAs with antisense complementarity to Lin-14. Cell 75: 843-854.
112. Ley, T.J., Mardis, E.R., Ding, L., Fulton, B., McLellan, M.D., Chen, K. et al. (2008) DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456: 66-72.
113. Li, J. and Makrigiorgos, G.M. (2009) Cold-PCR: a new platform for highly improved mutation detection in cancer and genetic testing. Biochem Soc Trans 37: 427-432.
114. Li, M., Lin, Y.M., Hasegawa, S., Shimokawa, T., Murata, K., Kameyama, M. et al. (2004) Genes associated with liver metastasis of colon cancer, identified by genome-wide cDNA microarray. Int J Oncol 24: 305-312.
115. Li, J., Martinka, M. and Li, G. ( 2008) Role of Ing 4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis 29: 1373-1379.
116. Li, Y., Sawalha, A.H. and Lu, Q. ( 2009) Aberrant DNA methylation in skin diseases. J Dermatol Sci 54: 143-149.
117. Lievre, A., Bachet, J.B., Le Corre, D., Boige, V., Landi, B., Emile, J.F. et al. (2006) Kras mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.
118. Lin, H.M., Chatterjee, A., Lin, Y.H., Anjomshoaa, A., Fukuzawa, R., McCall, J.L. et al. (2007 a) Genome wide expression profiling identifies genes associated with colorectal liver metastasis. Oncol Rep 17: 1541-1549.
119. Lin, Y.H., Friederichs, J., Black, M.A., Mages, J., Rosenberg, R., Guilford, P.J. et al. (2007 b) Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res 13: 498-507.
120. Linton, K., Hey, Y., Dibben, S., Miller, C., Freemont, A., Radford, J. et al. (2009) Methods comparison for high-resolution transcriptional analysis of archival material on Affymetrix Plus 2.0 and Exon 1.0 microarrays Biotechniques 47: 587-596.
121. Lipponen, P., Eskelinen, M., Syrjanen, S., Tervahauta, A. and Syrjanen, K. ( 1991) Use of immunohistochemically demonstrated C-Erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol 20: 238-242.
122. Lisboa, P.J., Etchells, T.A., Jarman, I.H., Aung, M.S., Chabaud, S., Bachelot, T. et al. (2007) Development of a rule based prognostic tool for her 2 positive breast cancer patients. Conf Proc IEEE Eng Med Biol Soc 1: 5416-5419.
123. Liu, R., Wang, X., Chen, G.Y., Dalerba, P., Gurney, A., Hoey, T. et al. (2007) The Prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356: 217-226.
124. Liukkonen, T., Lipponen, P., Raitanen, M., Kaasinen, E., Ala-Opas, M., Rajala, P. et al. (2000) Evaluation of P21waf1/Cip1 and cyclin D 1 expression in the progression of superficial bladder cancer. Finbladder Group. Urol Res 28: 285-292.
125. Logothetis, C.J., Xu, H.J., Ro, J.Y., Hu, S.X., Sahin, A., Ordonez, N. et al. (1992) Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 84: 1256-1261.
126. Ma, X.J., Wang, Z., Ryan, P.D., Isakoff, S.J., Barmettler, A., Fuller, A. et al. (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616.
127. Maitournam, A. and Simon, R. ( 2005) On the efficiency of targeted clinical trials. Stat Med 24: 329-339.
128. Mallardo, M., Poltronieri, P. and D'urso, O.F. ( 2008) Non-protein coding RNA biomarkers and differential expression in cancers: a review. J Exp Clin Cancer Res 27: 19.
129. Mandruzzato, S., Callegaro, A., Turcatel, G., Francescato, S., Montesco, M.C., Chiarion-Sileni, V. et al. (2006) A gene expression signature associated with survival in metastatic melanoma. J Transl Med 4: 50.
130. Mariadason, J.M., Arango, D., Shi, Q., Wilson, A.J., Corner, G.A., Nicholas, C. et al. (2003) Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and campto thecin. Cancer Res 63: 8791-8812.
131. Mascaux, C., Iannino, N., Martin, B., Paesmans, M., Berghmans, T., Dusart, M. et al. (2005) The role of ras oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92: 131-139.
132. Mass, R.D., Press, M.F., Anderson, S., Cobleigh, M.A., Vogel, C.L., Dybdal, N. et al. (2005) Evaluation of clinical outcomes according to Her 2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 6: 240-246.
133. McCormick, K.A. ( 2009) Individualizing cancer care with interoperable information systems. Stud Health Technol Inform 146: 383-390.
134. Mengual, L., Burset, M., Ars, E., Lozano, J.J., Villavicencio, H., Ribal, M.J. et al. (2009) DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers. J Urol 182: 741-748.
135. Meropol, N.J., Gold, P.J., Diasio, R.B., Andria, M., Dhami, M., Godfrey, T. et al. (2006) Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24: 4069-4077.
136. Metzger, R., Danenberg, K., Leichman, C.G., Salonga, D., Schwartz, E.L., Wadler, S. et al. (1998) High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4: 2371-2376.
137. Mitchell, P.S., Parkin, R.K., Kroh, E.M., Fritz, B.R., Wyman, S.K., Pogosova-Agadjanyan, E.L. et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513-10518.
138. Miyake, H., Eto, H., Arakawa, S., Kamidono, S. and Hara, I. ( 2002) Over Expression of Cd44v8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer. J Urol 167: 1282-1287.
139. Mostert, B., Sleijfer, S., Foekens, J.A. and Gratama, J.W. (2009) Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 35: 463-474.
140. Nagarajan, R.P. and Costello, J.F. (2009) Epigenetic mechanisms in glioblastoma multiforme. Semin Cancer Biol 19: 188-197.
141. Nagata, Y., Lan, K., Zhou, X., Tan, M., Esteva, F., Sahin, A. et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127.
142. Nakamura, S., Yagata, H., Ohno, S., Yamaguchi, H., Iwata, H., Tsunoda, N. et al. (2009) Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer. Epub 1 August 2009.
143. Nezos, A., Lembessis, P., Sourla, A., Pissimissi, N., Gogas, H. and Koutsilieris, M. (2009) Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance. Clin Chem Lab Med 47: 1-11.
144. Ng, S.B., Turner, E.H., Robertson, P.D., Flygare, S.D., Bigham, A.W., Lee, C. et al. (2009) Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461: 272-276.
145. Nguyen, P.L., Swanson, P.E., Jaszcz, W., Aeppli, D.M., Zhang, G., Singleton, T.P. et al. (1994) Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 101: 166-176.
146. NIH (2003) NIH data sharing policy and implementation guidance. http://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm.
147. Olaussen, K.A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V. et al. (2006) DNA repair by Ercc 1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991.
148. Oldenhuis, C.N.A.M., Oosting, S.F., Gietema, J.A. and de Vries, E.G.E. ( 2008) Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 44: 946-953.
149. Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M. et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826.
150. Paik, S., Kim, C.Y., Song, Y.K. and Kim, W.S. ( 2005) Technology insight: application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. Nat Clin Pract Oncol 2: 246-254.
151. Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W. et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24: 3726-3734.
152. Palomaki, G.E., Bradley, L.A., Douglas, M.P., Kolor, K. and Dotson, W.D. (2009) Can Ugt1a1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 11: 21-34.
153. Pao, W., Miller, V.A., Politi, K.A., Riely, G.J., Somwar, R., Zakowski, M.F. et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the egfr kinase domain. PLoS Med 2: e73.
154. Parkinson, H., Kapushesky, M., Shojatalab, M., Abeygunawardena, N., Coulson, R., Farne, A. et al. (2007) Arrayexpress-a public database of microarray experiments and gene expression profiles. Nucleic Acids Res 35: D747-D750
155. Penault-Llorca, F., Bilous, M., Dowsett, M., Hanna, W., Osamura, R.Y., Ruschoff, J. et al. (2009) Emerging technologies for assessing Her 2 amplification. Am J Clin Pathol 132: 539-548.
156. Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A. et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
157. Pertschuk, L.P., Gaetjens, E., Carter, A.C., Brigati, D.J., Kim, D.S. and Tobin, E.H. ( 1979) Histochemistry of steroid receptors in breast cancer: an overview. Ann Clin Lab Sci 9: 219-224.
158. Petricoin, E.F., Belluco, C., Araujo, R.P. and Liotta, L.A. ( 2006) The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 6: 961-967.
159. Phillips, K.A., Marshall, D.A., Haas, J.S., Elkin, E.B., Liang, S.Y., Hassett, M.J. et al. (2009) Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer 115: 5166-5174.
160. Pittman, J., Huang, E., Dressman, H., Horng, C.F., Cheng, S.H., Tsou, M.H. et al. (2004) Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A 101: 8431-8436.
161. Pitts, P.J. ( 2008) FDA and the critical path to twenty-first-century medicine. J Med Philos 3: 515-523.
162. Poston, G.J., Adam, R., Alberts, S., Curley, S., Figueras, J., Haller, D. et al. (2005) Oncosurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 23: 7125-7134.
163. Rakha, E.A., El-Sayed, M.E., Reis-Filho, J.S. and Ellis, I.O. ( 2008) Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology 52: 67-81.
164. Rangel, J., Torabian, S., Shaikh, L., Nosrati, M., Baehner, F.L., Haqq, C. et al. (2006) Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma. J Clin Oncol 24: 4565-4569.
165. Ransohoff, D.F. ( 2005) Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 5: 142-149.
166. Ravdin, P.M., Siminoff, L.A., Davis, G.J., Mercer, M.B., Hewlett, J., Gerson, N. et al. (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19: 980-991.
167. Reid, J.F., Lusa, L., de Cecco, L., Coradini, D., Veneroni, S., Daidone, M.G. et al. (2005) Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 97: 927-930.
168. Reschke, M., Mihic-Probst, D., van der Horst, E.H., Knyazev, P., Wild, P.J., Hutterer, M. et al. (2008) Her 3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 14: 5188-5197.
169. Richter, J., Wagner, U., Kononen, J., Fijan, A., Bruderer, J., Schmid, U. et al. (2000) High-throughput tissue microarray analysis of cyclin e gene amplification and overexpression in urinary bladder cancer. Am J Pathol 157: 787-794.
170. Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H. et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203.
171. Ring, B.Z., Seitz, R.S., Beck, R., Shasteen, W.J., Tarr, S.M., Cheang, M.C. et al. (2006) Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 24: 3039-3047.
172. Rogowski, W.H., Grosse, S.D. and Khoury, M.J. (2009) Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet 10: 489-495.
173. Rosell, R., Danenberg, K.D., Alberola, V., Bepler, G., Sanchez, J.J., Comps, C. et al. (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10: 1318-1325.
174. Rosell, R., Skrzypski, M., Jassem, E., Taron, M., Bartolucci, R. et al. (2007) BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PloS ONE 2: e1129.
175. Ross, J.S. (2009 a) Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. Adv Anat Pathol 16: 204-215.
176. Ross, J.S. ( 2009b) Breast cancer biomarkers and Her 2 testing after 10 years of anti-Her2 therapy. Drug News Perspect 22: 93-106.
177. Ross, J.S. and Slodkowska, E.A. (2009) Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol 132: 237-245.
178. Ross, J.S., Symmans, W.F., Pusztai, L. and Hortobagyi, G.N. ( 2007) Standardizing slide-based assays in breast cancer: hormone receptors, Her2, and sentinel lymph nodes. Clin Cancer Res 13: 2831-2835.
179. Ross, J.S., Hatzis, C., Symmans, W.F., Pusztai, L. and Hortobagyi, G.N. ( 2008) Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 13: 477-493.
180. Rouzier, R., Perou, C.M., Symmans, W.F., Ibrahim, N., Cristofanilli, M., Anderson, K. et al. (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685.
181. Rouzier, R., Pusztai, L., Delaloge, S., Gonzalez-Angulo, A.M., Andre, F., Hess, K.R. et al. (2005) Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23: 8331-8339.
182. Saidi, S.A., Holland, C.M., Kreil, D.P., Mackay, D.J., Charnock-Jones, D.S., Print, C.G. et al. (2004) Independent component analysis of microarray data in the study of endometrial cancer. Oncogene 23: 6677-6683.
183. Salter, K.H., Acharya, C.R., Walters, K.S., Redman, R., Anguiano, A., Garman, K.S. et al. (2008) An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PloS ONE 3: e1908.
184. Sawyers, C.L. ( 2008) The cancer biomarker problem. Nature 452: 548-552.
185. Scartozzi, M., Bittoni, A., Pistelli, M., Galizia, E., Berardi, R., Giampieri, R. et al. (2009) Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. Cancer Treat Rev 35: 451-462.
186. Scheuner, M.T., Sieverding, P. and Shekelle, P.G. ( 2008) Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA 299: 1320-1334.
187. Schmidt, C. ( 2008) Regulators weigh risks of consumer genetic tests. Nat Biotechnol 26: 145-146.
188. Schmitz-Drager, B.J., Goebell, P.J., Ebert, T. and Fradet, Y. ( 2000) P 53 Immunohistochemistry as a prognostic marker in bladder cancer Playground for urology scientists? Eur Urol 38: 691-699; discussion 700.
189. Sequist, L.V., Bell, D.W., Lynch, T.J. and Haber, D.A. ( 2007) Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25: 587-595.
190. Sergeant, G., Pennickx, F. and Topal, B. ( 2008) Quantitative RT-PCR detection of colorectal tumour cells in peripheral blood-a systematic review. J Surg Res 150: 144-152.
191. Seve, P., Lai, R., Ding, K., Winton, K., Butts, C., Mackey, J. et al. (2007) Class III beta-tubulin expression and benefit from adjuvant cisplatin / vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 13: 994-999.
192. Shah, S.P., Kobel, M., Senz, J., Morin, R.D., Clarke, B.A., Wiegand, K.C. et al. (2009) Mutation of Foxl 2 in granulosa-cell tumors of the ovary. N Engl J Med 360: 2719-2729.
193. Shedden, K.A., Taylor, J.M., Giordano, T.J., Kuick, R., Misek, D.E., Rennert, G. et al. (2003) Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. Am J Pathol 163: 1985-1995.
194. Shelling, A. ( 2009) Progress in the study of genetic disease: bringing new light to complex problems. Postgrad Med J 85.
195. Shendure, J. ( 2008) The beginning of the end for microarrays? Nat Methods 5: 585-587.
196. Shi, L., Reid, L.H., Jones, W.D., Shippy, R., Warrington, J.A., Baker, S.C. et al. (2006) The Microarray Quality Control (MAQC) Project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24: 1151-1161.
197. Shih, W., Chetty, R. and Tsao, M.S. ( 2005) Expression profiling by microarrays in colorectal cancer (review). Oncol Rep 13: 517-524.
198. Simon, R. ( 2005) Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 23: 7332-7341.
199. Simon, R., Radmacher, M.D., Dobbin, K. and McShane, L.M. ( 2003) Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95: 14-18.
200. Singer, S., Rubin, B.P., Lux, M.L., Chen, C.J., Demetri, G.D., Fletcher, C.D. et al. (2002) Prognostic value of kit mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 20: 3898-3905.
201. Skog, J., Wurdinger, T., van Rijn, S., Meijer, D.H., Gainche, L., Sena-Esteves, M. et al. (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10: 1470-1476.
202. Sleijfer, S., Gratama, J.W., Sieuwerts, A.M., Kraan, J., Marens, J.W. and Foekens, J.A. ( 2007) Circulating tumour cell detection on its way to routine diagnostic implementation? Eur J Cancer 43: 2645-2650.
203. Soleymani, L., Fang, Z., Sargent, E.H. and Kelley, S.O. (2009) Programming the detection limits of biosensors through controlled nanostructuring. Nat Nanotechnol 4: 844-848.
204. Solit, D.B., Garraway, L.A., Pratilas, C.A., Sawai, A., Getz, G., Basso, A. et al. (2006) Braf mutation predicts sensitivity to Mek inhibition. Nature 439: 358-362.
205. Sorlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H. et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874.
206. Sorlie, T., Perou, C.M., Fan, C., Geisler, S., Aas, T., Nobel, A. et al. (2006) Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther 5: 2914-2918.
207. Sotiriou, C. and Piccart, M.J. ( 2007) Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 7 (7): 545-553.
208. Sotiriou, C. and Pusztai, L. (2009) Gene-expression signatures in breast cancer. N Engl J Med 360: 790-800.
209. Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J. et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272.
210. Sotiropoulou, G., Pampalakis, G., Lianidou, E. and Mourelatos, Z. (2009) Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA 15: 1443-1461.
211. Sreekumar, A., Poisson, L.M., Rajendiran, T.M., Khan, A.P., Cao, Q., Yu, J. et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910-914.
212. Stein, J.P., Ginsberg, D.A., Grossfeld, G.D., Chatterjee, S.J., Esrig, D., Dickinson, M.G. et al. (1998) Effect of P21waf1/Cip1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 90: 1072-1079.
213. Sykacek, P., Clarkson, R., Print, C., Furlong, R. and Micklem, G. ( 2007) Bayesian modelling of shared gene function. Bioinformatics 23: 1936-1944.
214. Symmans, W.F., Ayers, M., Clark, E.A., Stec, J., Hess, K.R., Sneige, N. et al. (2003) Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97: 2960-2971.
215. Tang, F., Barbacioru, C., Wang, Y., Nordman, E., Lee, C., Xu, N. et al. (2009) mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods 6: 377-382.
216. Tavassoli, F.A. ( 2009) Challenges in breast pathology: new twists on old problems. Arch Pathol Lab Med 133: 852-854.
217. Tenesa, A. and Dunlop, M.G. ( 2009) New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet. Epub 12 May 2009.
218. Thakur, M.L. ( 2009) Genomic biomarkers for molecular imaging: predicting the future. Semin Nucl Med 39: 236-246.
219. Thiagalingam, S. ( 2006) A cascade of modules of a network defines cancer progression. Cancer Res 66: 7379-7385.
220. Thomas, R.K., Nickerson, E., Simons, J.F., Janne, P.A., Tengs, T., Yuza, Y. et al. (2006) Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 12: 852-855.
221. Tinker, A.V., Boussioutas, A. and Bowtell, D.D. ( 2006) The challenges of gene expression microarrays for the study of human cancer. Cancer Cell 9: 333-339.
222. Toriello, N.M., Douglas, E.S., Thaitrong, N., Hsiao, S.C., Francis, M.B., Bertozzi, C.R. et al. (2008) Integrated microfluidic bioprocessor for single-cell gene expression analysis. Proc Natl Acad Sci U S A 105: 20173-20178.
223. Tsao, M., Aviel-Ronen, S., Ding, K., Lau, D., Liu, N., Sakurada, A. et al. (2007) Prognostic and predictive importance of p 53 and Ras for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 25: 5240-5247.
224. Tunuguntla, H.S. and Jorda, M. ( 2008) Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol 179: 2096-2102.
225. Vallbohmer, D., Iqbal, S., Yang, D.Y., Rhodes, K.E., Zhang, W., Gordon, M. et al. (2006) Molecular determinants of irinotecan efficacy. Int J Cancer 119: 2435-2442.
226. van Cutsem, E., Kohne, C.H., Hitre, E., Zaluski, J., Chang Chien, C.R., Makhson, A. et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417.
227. van de Vijver, M.J., He, Y.D., van ‘t Veer, L.J., Dai, H., Hart, A.A., Voskuil, D.W. et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
228. van Laar, R.K., Ma, X.J., de Jong, D., Wehkamp, D., Floore, A.N., Warmoes, M.O. et al. (2009) Implementation of a novel microarray-based diagnostic test for cancer of unknown primary. Int J Cancer 125: 1390-1397.
229. van ‘t Veer, L.J., Dai, H., van de Vijver, M.J., He, Y.D., Hart, A.A., Mao, M. et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
230. Venables, J.P. ( 2006) Unbalanced alternative splicing and its significance in cancer. Bioessays 28: 378-386.
231. Wanebo, H.J., Rao, B., Pinsky, C.M., Hoffman, R.G., Stearns, M., Schwartz, M.K. et al. (1978) Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 299: 448-451.
232. Wang, Y., Klijn, J.G., Zhang, Y., Sieuwerts, A.M., Look, M.P., Yang, F. et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
233. Wang, Y., Dai, D.L., Martinka, M. and Li, G. ( 2007) Prognostic significance of nuclear Ing 3 expression in human cutaneous melanoma. Clin Cancer Res 13: 4111-4116.
234. Wang, X., Liu, L., Fackenthal, J., Cummings, S., Olopade, O.I., Hope, K. et al. (2009 a) Translational integrity and continuity: personalized biomedical data integration. J Biomed Inform 42: 100-112.
235. Wang, Z., Gerstein, M. and Snyder, M. (2009 b) RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10: 57-63.
236. Watanabe, T., Wu, T.T., Catalano, P.J., Ueki, T., Satriano, R., Haller, D.G. et al. (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344: 1196-1206.
237. Weigelt, B., Hu, Z., He, X., Livasy, C., Carey, L.A., Ewend, M.G. et al. (2005) Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 65: 9155-9158.
238. West, M., Blanchette, C., Dressman, H., Huang, E., Ishida, S., Spang, R. et al. (2001) Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 98: 11462-11467.
239. Winnepenninckx, V., Lazar, V., Michiels, S., Dessen, P., Stas, M., Alonso, S.R. et al. (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98: 472-482.
240. Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C. et al. (2005) Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med 352: 2589-2597.
241. Wolmark, N., Fisher, B., Wieand, H.S., Henry, R.S., Lerner, H., Legault-Poisson, S. et al. (1984) The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) Clinical Trials. Ann Surg 199: 375-382.
242. Wuttig, D., Baier, B., Fuessel, S., Meinhardt, M., Herr, A., Hoefling, C. et al. (2009) Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. Int J Cancer 125: 474-482.
243. Xi, L., Feber, A., Gupta, V., Wu, M., Bergemann, A.D., Landreneau, R.J. et al. (2008) Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res 36: 6535-6547.
244. Xu, K., Hou, S. and Du, Z. ( 2002) Prognostic value of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in bladder carcinoma. Chin Med J 115: 743-745.
245. Zheng, Z., Chen, T., Li, X., Haura, E., Sharma, A. and Bepler, G. ( 2007) DNA synthesis and repair genes Rrmi and Ercc 1 in lung cancer. N Engl J Med 356: 800-808.
246. Zhu, C.Q., Da Cunha Santos, G., Ding, K., Sakurada, A., Cutz, J.C., Liu, N. et al. (2008) Role of Kras and Egfr as Biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study Br.21. J Clin Oncol 26: 4268-4275.
247. Zhu, W., Qin, W., Atasoy, U. and Sauter, E.R. (2009) Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes 2: 89.
248. Zujewski, J.A. and Kamin, L. ( 2008) Trial assessing individualized options for treatment for breast cancer: the Tailorx trial. Future Oncol 4: 603-610.